Sandra Panem Director Stock Option Holdings in BioLineRx Ltd.

This Form 3 filing discloses the stock option holdings of Sandra Panem, a director of BioLineRx Ltd. (BLRX). The filing reports multiple employee stock option grants dating from 2016 to 2024, with exercise prices ranging from $0.052 to $0.920 per share. The most significant holdings include a 2022 grant for 1,080,000 options at $0.085, a 2023 grant for 360,000 options at $0.081, and a 2024 grant for 360,000 options at $0.085. Additionally, a substantial October 2024 grant of 2,055,000 options at $0.052 is reported, with 856,200 options already vested and the remaining 1,198,800 vesting quarterly over 7 installments. All options are fully vested except for the 2024 grant, which has ongoing vesting. The filing provides a comprehensive view of the director's equity compensation over nearly a decade.